Furthermore, our recent report that CADD522 activates theHippo tumor suppressor pathway in luminal breast cancer [16] suggests a compensatory pathway to overcome the potential drawback of RUNX3 inhibition by CADD522. Here, RUNX3 is linked to breast cancer.